The Clinical Trial Agreement for biopharmaceutical industry sponsored research in primary care (Primary Care mCTA) has been developed and approved by the Association of the British Pharmaceutical Industry, the BioIndustry Association, a number of highly active general practitioners, the British Medical Association, the Protection Medical Society and UK health authorities. The Health Research Authority (HRA) supports the application of standard agreements. Clinical trials play a central role in the development of safe drugs and medical devices on the market and, of course, are within a broad Irish, community and international framework of rules, codes of conduct and guidelines. A well-developed clinical trial agreement creates legal obligations and rights for the parties. National site location agreements help speed up the process of awarding trials in the NHS supported by industry, as there is no longer a need for site-by-site controls and local legal agreements. This allows studies to start earlier, improve the speed of industry-sponsored clinical trials and enable patients with NHS to access innovative treatments more quickly. The range of model location agreements is supported by guidelines that specify the objectives and modalities of the use of the agreement in the development of clinical research contracts supported by pharmaceutical, biopharmaceutical or medical companies. Primary Care mCTA was designed to simplify and expedite the process of stopping and initiating pharmaceutical and biopharmaceutical clinical trials on primary care patients. The intention is that the mCTA Primary Care Centre will be used regularly without modification by all promoters of the pharmaceutical and biopharmaceutical industry of contract clinical research, where patients with NHS are recruited into primary care. In such cases, no further legal review is required, saving money and time.
These model agreements apply to health services in England, Northern Ireland, Scotland and Wales; they replace the 2011 country versions. The accompanying guidelines provide more general information, an overview of changes from the 2011 versions, and additional information on how models should be used and under what circumstances. We found in this study a lack of knowledge of the members of the ethics committee with respect to CTA and clinical insurance. Even the ethical guidelines have only begun to tell them in recent years.  One of the missions of the International Electrical Engineering Commission (IEC) is to verify whether appropriate measures have been taken to protect the rights of the participants concerned in the event of a mine- leading or lethal study or in the event of a premature termination of the clinical trial. Knowledge of the CTA and the insurance document for clinical trials is therefore important to CIS members. A previous study in India showed that 30% of institutions had guidelines for the management of research-related injury compensation, and 83% of ethics committee members did not know the details of the insurance contract.  In the current regulatory scenario, it is necessary in India for CIS members to be familiar with both the insurance and the CTA. This study highlights the need to train ethics committee members on ATCs and clinical trial insurance. Clinical trial agreements must be developed with due consideration in light of the most current legal framework and related guidelines.